Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05386394 · ClinicalTrials.gov registry record · Phase 2
Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia
A Phase 2 study of Primary Progressive Aphasia and Logopenic Progressive Aphasia, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 3
- Study locations
NCT05386394 is a Phase 2 study of Primary Progressive Aphasia and Logopenic Progressive Aphasia that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 180 participants, above the 81-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (122% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT05386394, a Phase 2 study of Primary Progressive Aphasia and Logopenic Progressive Aphasia, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 3
- Study locations
Study Summary
While many have strongly suggested that transcranial direct current stimulation (tDCS) may represent a beneficial intervention for patients with primary progressive aphasia (PPA), this promising technology has not yet been applied widely in clinical settings. This treatment gap is underscored by the absence of any neurally-focused standard-of-care treatments to mitigate the devastating impact of aphasia on patients' family, work, and social lives. Given that tDCS is inexpensive, easy to use (it is potentially amenable to home use by patients and caregivers), minimally invasive, and safe there is great promise to advance this intervention toward clinical use. The principal reason that tDCS has not found wide clinical application yet is that its efficacy has not been tested in large, multi-center, clinical trials. In this study, scientists in the three sites that have conducted tDCS clinical trials in North America-Johns Hopkins University and the University of Pennsylvania in the US, and the University of Toronto in Canada, will collaborate to conduct a multi-site, Phase II clinical trial of tDCS a population in dire need of better treatments.
Conditions Studied
Interventions
- DEVICE Active tDCS + Language Therapy
- DEVICE Sham tDCS + Language Therapy
Study Locations (3)
Maryland
- Johns Hopkins Hospital - Baltimore
Pennsylvania
- University of Pennsylvania - Philadelphia
Ontario
- Baycrest Centre for Geriatric Care - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2024-02-13 |
| Est. Completion | 2028-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05386394
The ClinicalTrials.gov registry entry for NCT05386394 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 81-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (122% higher). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Primary Progressive Aphasia appearing as the primary indexed condition, and to 2 interventions - of which Active tDCS + Language Therapy is the first listed.
NCT05386394 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Pennsylvania, Ontario.
Frequently Asked Questions
What is clinical trial NCT05386394 about?
NCT05386394 is a clinical study titled "Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia". While many have strongly suggested that transcranial direct current stimulation (tDCS) may represent a beneficial intervention for patients with primary progressive aphasia (PPA), this promising technology has not yet been applied widely in clinical settings. This treatment gap is underscored by the...
What is the current status of trial NCT05386394?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2024-02-13. Estimated completion is 2028-02-01.
What conditions does trial NCT05386394 study?
This clinical trial studies the following conditions: Primary Progressive Aphasia, Logopenic Progressive Aphasia, Non-Fluent Primary Progressive Aphasia.
What interventions are being tested in trial NCT05386394?
The interventions under investigation include: Active tDCS + Language Therapy (DEVICE), Sham tDCS + Language Therapy (DEVICE).
Who is sponsoring clinical trial NCT05386394?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05386394 being conducted?
This trial has 3 study locations across Maryland, Pennsylvania, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Progressive Aphasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Communication Bridge 3 Study
RECRUITING · Phase 2
-
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
RECRUITING · Phase 4
-
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
RECRUITING
-
Language in Primary Progressive Aphasia
RECRUITING
-
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
RECRUITING · Early Phase 1
-
Enhancing Language Function in Aphasia
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.